<DOC>
	<DOCNO>NCT00740597</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study side effect intensity-modulated radiation therapy see well work treat patient undergo surgery stage IB , stage II , stage III soft tissue sarcoma .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy Treating Patients Undergoing Surgery Stage IB , Stage II , Stage III Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Estimate wound complication rate patient stage IB-III soft tissue sarcoma ( STS ) treat neoadjuvant intensity-modulated radiotherapy ( IMRT ) . Secondary - Assess local control rate patient treat regimen . - Assess metastatic failure rate patient treat regimen . - Assess disease-free survival patient treat regimen . - Assess overall survival patient treat regimen . - Assess function general health patient use Musculoskeletal Tumor Society rating scale , Toronto Extremity Salvage Score , Short-Form 36 . - Determine change STS gene expression IMRT microarray analysis . - Correlate , preliminarily , change STS gene expression pathological clinical outcome . OUTLINE : Patients undergo intensity-modulated radiotherapy ( IMRT ) daily 5 day week 5 week absence disease progression unacceptable toxicity . Patients undergo surgery &gt; 1 month completion IMRT . Tumor tissue sample collect baseline time surgery correlative laboratory study . Samples analyze gene expression RNA microarray , real-time polymerase chain reaction , western blotting . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm soft tissue sarcoma ( STS ) neoadjuvant adjuvant radiotherapy consider standard care Stage IBIII disease Primary locally recurrent disease The following chemotherapysensitive STS histology exclude : Primitive neuroectodermal tumor Desmoplastic small round cell tumor Synovial sarcoma Myxoid round cell liposarcoma Angiosarcoma No sarcoma surgical staging adjuvant radiotherapy consider standard care ( e.g. , uterine sarcoma , include leiomyosarcoma , malignant mixed MÃ¼llerian tumor , endometrial stromal sarcoma ) No retroperitoneal STS PATIENT CHARACTERISTICS : ECOG performance status 02 Able complete selfassessment questionnaire ( may use translator service ) Willing able undergo pretreatment core needle biopsy Negative pregnancy test No know HIV positivity PRIOR CONCURRENT THERAPY : Prior adjuvant chemotherapy STS allow provide patient locally recurrent disease At least 1 year since prior adjuvant chemotherapy No prior radiotherapy site present STS No concurrent cytotoxic chemotherapy , target therapy , investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult extraskeletal chondrosarcoma</keyword>
	<keyword>adult extraskeletal osteosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>dermatofibrosarcoma protuberans</keyword>
</DOC>